

Symposium

202



# Evolving Therapies in Clinical Practice in IBD

April 29 – 30, 2016

Hilton Prague

Prague, Czech Republic



## Program

Awarded  
with

**12**  
CME credits

▶	Preface . . . . .	4
▶	Scientific Program . . . . .	6
▶	Posters. . . . .	11
▶	List of Speakers, Moderators and Scientific Organizers . . . . .	19
▶	Information . . . . .	22

12 credit hours (CME) have been awarded for the Symposium 202 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).

## Preface

Dear colleagues,  
Dear IBD friends,

It is our great pleasure to cordially invite you to the Symposium 202 to be held in Prague, Czech Republic in April, 2016. There is no doubt that the therapy of IBD has evolved substantially since the last Falk Symposium in Prague thirteen years ago, and this progress continues. The upcoming symposium "Evolving Therapies in Clinical Practice in IBD" will focus on several aspects of current IBD management. Introduction of new, pathophysiology-based therapies, discussion on unmet needs, presentation of promising experimental methods as well as improvements in currently used therapeutic modalities all comprise the core of the program. Moreover, you will also have great opportunities to discuss challenging cases requiring a multidisciplinary approach and close cooperation between IBD specialists.

We believe that the outstanding faculty of this Symposium, together with both the renowned organization by the Falk Foundation and the famous spirit of the Czech capital will entice many colleagues to accept this invitation. At the same time, we would like to express our gratitude to Mrs. Ursula Falk and the Falk Foundation for giving us the opportunity to organize this highly prestigious meeting.

On behalf of the scientific organizers,



Prof. Dr. Milan Lukas, Prague



# Evolving Therapies in Clinical Practice in IBD

April 29 – 30, 2016  
Hilton Prague  
Prague, Czech Republic

## Registration:

Thursday, April 28, 2016  
16.00 – 21.00 h  
at the congress office

## Scientific Organization:

M. Bortlik, Prague (Czech Republic)  
W. Kruis, Cologne (Germany)  
M. Lukas, Prague (Czech Republic)  
E. F. Stange, Stuttgart (Germany)

## Congress Venue:

Hilton Prague  
Pobrezni 1  
18600 Prague 8  
Czech Republic

## Information:

Prof. Dr. Milan Lukas  
Clinical and Research  
Center for IBD  
Iscore I.V.F. a.s., Lighthouse  
Jankovcova 1569/2c  
170 04 Prague  
Czech Republic  
Telephone: +420 234 770 299  
Telefax: +420 234 770 300  
E-Mail: milan.lukas@email.cz

## Official Language:

English

## Posters:

A poster session will take place.  
For details see page 11.

## ► Friday, April 29, 2016

- 8.30** Welcome and introduction E. F. Stange, Stuttgart
- 8.40** Progress in our understanding of IBD M. Lukas, Prague

### Session I Novel therapeutic approaches in medical therapy

**Chair:** M. Lukas, Prague; E. F. Stange, Stuttgart

- 9.00** Anticytokine strategy beyond the anti-TNF-alpha therapy – Pathophysiology and clinical implication G. Rogler, Zurich
- 9.30** Leukocyte anti-trafficking strategy: Current status and future directions B. E. Sands, New York
- 10.00** Improvement of “leaky” intestinal barrier E. F. Stange, Stuttgart
- 10.30** Coffee break with poster session

### Session II Unmet therapeutic needs: Focus on intestinal fibrosis

**Chair:** W. Kruis, Cologne; B. E. Sands, New York

- 11.00** Pathogenesis of intestinal fibrosis in IBD and perspectives for therapeutic implication F. Rieder, Cleveland
- 11.30** Do we have a reliable marker of intestinal fibrosis in clinical practice? The role of biochemical markers and imaging methods P. D. R. Higgins, Ann Arbor
- 12.00** Surgical approach: Resection, strictureplasty and others Y. Panis, Paris
- 12.30** Lunch break with poster session

# ► Friday, April 29, 2016

## Session III

### Interactive Session: How to improve our care in IBD?

**Chair:** M. Bortlik, Prague; Z. Zelinkova, Bratislava

- 13.30** Case report:  
Perianal Crohn's disease requiring complex management  
P. L. Lakatos, Budapest
- What should be done in perianal CD?  
Surgeon's statement  
Z. Serclova, Prague
- 14.00** Case report:  
Acute severe ulcerative colitis  
A. E. Dorofeyev, Kiev
- What should be done in patients with acute severe UC?  
Is there a role for second rescue therapy or is surgery required?  
M. Martí Gallostra, Barcelona
- 14.30** Case report:  
Immunosuppressive therapy in patients with IBD and malignancy  
G. Novacek, Vienna
- What should be done in IBD patients with prior malignancy?  
J. Cosnes, Paris
- 15.00** **Coffee break with poster session**

## Session IV

### How to best use the drugs?

**Chair:** M. Ferrante, Leuven; P. L. Lakatos, Budapest

- 15.30** Impact of perioperative medical therapy on surgical outcome  
A. Dignass, Frankfurt
- 16.00** Promise and danger of combination therapy  
W. Kruis, Cologne
- 16.30** Relevance of drug levels and antibodies in clinical practice  
A. Gils, Leuven

# Friday, April 29, 2016

## Special Lecture

**Chair:** G. Novacek, Vienna

**17.00** What can we learn from epidemiological studies in IBD? D. Duricova,  
Prague

**17.30** End of afternoon session

# ▶ Saturday, April 30, 2016

## Session V

### Biosimilars in clinical practice

**Chair:** T. Hlavaty, Bratislava; B. Moum, Oslo

- 9.00** State-of-the-Art Lecture:  
Does introduction of biosimilars change  
our understanding of track treatment? B. Moum,  
Oslo

### Early results:

### Focus on European experience

- 9.20** Experience with biosimilar infliximab (Remsima®)  
in Norway J. Jahnsen,  
Nordbyhagen
- 9.45** Biosimilar infliximab interchangeability in clinical  
practice in the Czech Republic M. Lukas,  
Prague
- 10.10** Immunogenicity and side effects of biosimilar infliximab  
treatment in Hungary P. L. Lakatos,  
Budapest
- 10.35** **Coffee break with poster session**

## Session VI

### Transplantation procedures in the therapy of IBD

**Chair:** C. J. Hawkey, Nottingham; J. Schölmerich, Frankfurt

- 11.00** Randomised controlled clinical trial of autologous  
haemopoietic stem cell transplantation in Crohn's  
disease C. J. Hawkey,  
Nottingham
- 11.20** Mesenchymal stem cell therapy in Crohn's disease G. M. Forbes,  
Perth
- 11.40** Fecal transplantation W. Reinisch,  
Hamilton
- 12.00** Small bowel transplantation P. Drastich,  
Prague
- 12.20** **Presentation of poster awards** E. F. Stange,  
Stuttgart
- 12.30** **Lunch break with poster session**



# ▶ Saturday, April 30, 2016

## Session VII Challenging clinical cases

**Chair:** Y. Panis, Paris; E. F. Stange, Stuttgart

- |              |  |                               |
|--------------|--|-------------------------------|
| <b>13.45</b> | Case reports: May both diseases (CD and UC) exist in one patient?                      | M. Bortlik,<br>Prague         |
| <b>13.55</b> | Overview: Complications after IPAA   | T. Molnár,<br>Szeged          |
| <b>14.20</b> | Case report: Acute flare of ulcerative colitis during pregnancy is still a big problem | M. Protic,<br>Belgrade        |
| <b>14.30</b> | Overview: What should be done in pregnant women with severe UC?                        | Z. Zelinkova,<br>Bratislava   |
| <b>14.55</b> | Case report: Ileal Crohn's disease in monozygotic twins                                | M. Diculescu,<br>Bucharest    |
| <b>15.05</b> | Overview: Limited CD in terminal ileum. Which therapy has to be the first choice?      | J. Orhalmi,<br>Hradec Králové |
| <b>15.30</b> | <b>Coffee break with poster session</b>  |                               |

## Special Lecture

**Chair:** W. Kruis, Cologne

- |              |  |                                   |
|--------------|--|-----------------------------------|
| <b>16.00</b> | Intestinal microbiome: Myths and facts | H. Tlaskalová-Hogenová,<br>Prague |
| <b>16.30</b> | <b>Conclusions</b>                     | M. Lukas,<br>Prague               |

## Poster Session

Posters will be exhibited on April 29-30, 2016 in the Hilton Prague. The authors will be in attendance during coffee and lunch breaks on both days.

1. Clinicians' knowledge about the ionizing radiation of the common investigations used in inflammatory bowel disease  
L. Alrubaiy, S. Al-Rubaye, I. Rikaby, C.L. Ch'ng (Swansea, London, GB)
2. Inflammatory bowel disease in the UK: Is care improving?  
L. Alrubaiy, I. Arnott, A. Protheroe, M. Roughton, J.G. Williams (Swansea, Edinburgh, London, GB)
3. Evaluation of fecal calprotectin to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) in Qena, Egypt  
M. Alsenbesy, A. Sabra, S. Sayed, M. Kabbash (Qena, EG)
4. Predictive factors for surgery and postoperative complications in patients with chronic inflammatory bowel disease  
S. Ayadi, M. Cheikh, R. Ennaifer, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
5. Role of the mean platelet volume as a marker of inflammation in Crohn's disease  
N. Ben Mustapha, O. Gharbi, I. Gheribi, A. Laabidi, M. Serghini, L. Kallel, M. Fekih, J. Boubaker, A. Filali (Tunis, TN)
6. Mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease  
N.J. Beres, Z. Kiss, D. Szücs, K.E. Müller, A. Cseh, Z. Sztupinszki, G. Lendvai, A. Arato, E. Sziksz, A. Vannay, A.J. Szabo, G. Veres (Budapest, Szeged, HU)
7. Iron deficiency anaemia in inflammatory bowel disease – The psychological, clinical and financial impact of first line intravenous iron therapy  
A.J. Boal, S.I. Squires, G.D. Naismith (Paisley, GB)
8. Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients  
C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, G. Lecca, C. Corrado, P. Vernia, P. Paoluzi, E.S. Corazziari (Rome, IT)
9. Digestive strictures complicating Crohn's disease: Clinical and therapeutic features  
M. Cheikh, I. Ben Aounallah, R. Ennaifer, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
10. Tolerance and efficacy of azathioprine in the treatment of chronic inflammatory bowel disease  
M. Cheikh, S. Ayadi, H. Romdhane, R. Ennaifer, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
11. Clinical outcomes of ulcerative colitis patients treated with 5-aminosalicylates after a first course of corticosteroids  
W. Dahmani, W. Ben Mansour, A. Guedich, M.H. Loghmari, O. Hellara, F. Bdioui, L. Safer, H. Saffar (Monastir, TN)

12. Risk factors for colectomy in ulcerative colitis patients with severe flare-up  
W. Dahmani, W. Ben Mansour, A. Guedich, M.H. Loghmari, O. Hellara, F. Bdioui, L. Safer, H. Saffar (Monastir, TN)
13. Cigarette smoke modulates the effect of dextran sulfate sodium (DSS)-induced colitis on subpopulation of T cells in blood and colon in mice  
J. Daniluk, U. Daniluk, M. Rusak, J. Reszec, M. Dabrowska, A. Dabrowski (Bialystok, PL)
14. Non-invasive markers for diagnosis and determination of the severity of Crohn's disease in children – Preliminary study  
U. Daniluk, I. Werpachowska, J. Daniluk, J.M. Lotowska, D.M. Lebensztejn (Bialystok, PL)
15. Evaluation of angiogenesis in colorectal cancer associated with ulcerative colitis  
C.I. Deliu, M.C. Bezna, A. Genunche-Dumitrescu, D. Neagoe, D. Oana, N. Deliu (Craiova, RO)
16. Prevalence of articular disorder in patients with inflammatory bowel disease  
C.I. Deliu, M.C. Bezna, A. Genunche-Dumitrescu, N. Deliu, D. Negaoe (Craiova, RO)
17. Frequency of adverse skin reactions in patients treated with the anti-TNF therapy  
C.I. Deliu, M.C. Bezna, A. Genunche-Dumitrescu, O.M. Diaconu, D. Neagoe (Craiova, RO)
18. The condition of the intestinal microflora in patients with ulcerative colitis combined with hepatic steatosis  
L. Demeshkina, E.V. Zygalo, V. Didenko (Dnipropetrovsk, UA)
19. Ulcerative proctitis patients presenting with minimal rectal bleeding may be overlooked  
A. Demirezer Bolat, H. Koseoglu, O. Tayfur Yurekli, S. Ulutas, F.E. Akin, N.S. Büyükasik, O. Ersoy (Ankara, TR)
20. Adverse reactions versus benefits of anti-TNF agents in inflammatory bowel disease  
O.M. Diaconu, A.-M. Bedelici, C.I. Deliu, A. Genunche-Dumitrescu (Craiova, RO)
21. The prevalence of extraintestinal manifestations in patients with inflammatory bowel disease  
O.M. Diaconu, C.I. Deliu, A.-M. Bedelici, A. Genunche-Dumitrescu (Craiova, RO)
22. Tumor necrosis factor- $\alpha$ , resistin, leptin and ghrelin in ulcerative colitis  
O. El-Segai, H. Elbatae, A. Wageeh, G. Ismail, M. Eldomery (Tanta, Khafir El-Sheikh, EG)
23. Management of intra-abdominal abscesses in Crohn's disease: A monocentric Tunisian experience  
R. Ennaifer, H. Ayadi, B. Bouchabou, M. Cheikh, H. Romdhane, H. Ben Nejma, W. Bougassas, N. Belhadj (Tunis, TN)
24. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: A Tunisian monocentric study  
R. Ennaifer, B. Bouchabou, H. Ayadi, H. Romdhane, M. Cheikh, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)

25. Tuberculous versus Crohn's anal fistula: Diagnostic difficulties in endemic area  
R. Ennaifer, H. Ayadi, B. Bouchabou, M. Cheikh, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
26. Tuberculosis screening before anti-TNF- $\alpha$  therapy in an endemic country  
R. Ennaifer, B. Bouchabou, H. Ayadi, M. Cheikh, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
27. Toxicity of thiopurines in patients with inflammatory bowel disease: Frequency and risk factors  
M. Fekih, A. Laabidi, L. Kallel, M. Amri, N. Ben Mustapha, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)
28. Comparison of severe acute colitis inaugurating inflammatory bowel disease to followed IBD complicated by SAC  
M. Fekih, A. Laabidi, L. Kallel, M. Hafi, M. Serghini, N. Ben Mustapha, J. Boubaker, A. Filali (Tunis, TN)
29. Can we predict response to cyclosporine as second-line therapy in patients with severe acute colitis of inflammatory bowel disease?  
M. Fekih, A. Laabidi, M. Serghini, M. Bejaoui, J. Boubaker, L. Kallel, A. Filali (Tunis, TN)
30. Smoking status and response to thiopurines in inflammatory bowel disease patients  
A. Filali, N. Ben Mustapha, L. Kallel, H. Hassine, J. Boubaker, M. Serghini, J. Boubaker (Tunis, TN)
31. The role of the innate immune components in predicting the risk of early relapse of Crohn's disease  
A. Galushkin, L. Mamedova, G.N. Tarasova (Rostov-on-Don, RU)
32. Quality of life and late diagnosis of inflammatory bowel disease  
O. Gavrilesco, M. Dranga, I. Popa, M. Palaghia, M.A. Badea, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)
33. Anemia and quality of life in inflammatory bowel disease  
O. Gavrilesco, I. Ungureanu, R. Popa, A. Didita, M. Dranga, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)
34. The distinctive features of the therapy for induction of remission of the moderate UC in patients with HBV or HCV infection  
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea, C.I. Deliu, O.M. Diaconu (Craiova, RO)
35. The immunosuppressive therapy in induction of remission of the steroid-refractory ulcerative colitis in elderly patients  
A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea, C.I. Deliu (Craiova, RO)
36. Metabolic syndrome is also prevalent in inflammatory bowel disease  
O. Gharbi, I. Gheribi, N. Ben Mustapha, A. Laabidi, M. Serghini, L. Kallel, M. Fekih, J. Boubaker, A. Filali (Tunis, TN)

37. Mean platelet volume: A predictor of therapeutic response to azathioprine in Crohn's disease  
O. Gharbi, I. Gheribi, N. Ben Mustapha, A. Laabidi, M. Serghini, L. Kallel, M. Fekih, J. Boubaker, A. Filali (Tunis, TN)
38. Role of the neuropeptides in ulcerative colitis before treatment and in remission  
Z. Gök Sargin, N. Erin, B. Yildirim, Ö. Elpek, E. Alkan (Ankara, Antalya, Burdur, TR)
39. Tissue telomerase activity and plasma basic fibroblast growth factor as markers for early detection of dysplasia in chronic ulcerative colitis patients  
H. Hamooda, A. Balaash, S. Ismail, H. Elbatae, M. Eldomery, H. Youssef (Tanta, Khafra El-Sheikh, EG)
40. Extraintestinal manifestations in 112 cases of inflammatory bowel disease: Prevalence, types, predisposing factors  
L. Hamzaoui, M. Medhioub, O. Ghannei, H. Sahli, M.M. Azouz (Nabeul, TN)
41. Iatrogenic colorectal Kaposi sarcoma complicating a refractory ulcerative colitis in a human immunodeficiency virus-negative patient  
L. Hamzaoui, M. Mahmoudi, M. Bouassida, E. Chelbi, M.M. Azouz (Nabeul, TN)
42. Acute abdomen in Crohn's disease patients: Comparative study between first diagnosed at surgery and known Crohn's disease  
H. Hassine, H. Elloumi, D. Trad, N. Bibani, M. Sabbah, A. Oaukaa, D. Gargouri, J. Kharrat (Tunis, TN)
43. Clinical features of elderly-onset ulcerative colitis  
H. Hassine, H. Elloumi, N. Bibani, D. Trad, M. Sabbah, A. Oaukaa, D. Gargouri, J. Kharrat (Tunis, TN)
44. Predictive factors of postoperative morbidity and mortality in acute severe colitis  
O. Hellara, A. Hammami, W. Ben Mansour, H. Loghmari, W. Bouhleb, F. Bdioui, L. Safer, H. Saffar (Monastir, TN)
45. The economic burden and prevalence of inflammatory bowel disease (IBD) from 2010 to 2014 in Korea  
K. Hyo Jong, L. Chang Kyun, R. Sang Youl (Seoul, KR)
46. The clinical features of patients with newly diagnosed ulcerative colitis (UC) in Korea: A population-based inception cohort study  
K. Hyo Jong, L. Chang Kyun (Seoul, KR)
47. Enhanced atherogenesis and altered high-density lipoprotein in patients with Crohn's disease  
D. Janelidze, N. Omanidze (Kiev, UA)
48. Latent TB in IBD patients receiving anti-TNF therapy  
M. Jelakovic, D. Baricevic, M. Brinar, D. Grgic, A. Kunovic, R. Prijic, N. Turk, Z. Krznaric, B. Vucelic, S. Cukovic-Cavka (Zagreb, HR)
49. FXR-mediated induces expression of miR29a3p in colonic epithelial cells: Implications for therapy of inflammatory bowel disease  
S.J. Keely, A.M. O'Dwyer (Dublin, IE)

50. Inflammatory bowel disease patients' group with hepatobiliary manifestation.  
Results of 5-year experience  
N.V. Kharchenko, I. Lopukh, D. Janelidze (Kiev, UA)
51. Management of intra-abdominal collections complicating Crohn's disease:  
Experience of a Tunisian center  
A. Khsiba, M. Fekih, M. Hafi, I. Ghribi, J. Boubaker, L. Kallel, A. Filali (Tunis, TN)
52. MicroRNA expression in the colonic mucosa of pediatric patients with eosinophilic  
colitis in comparison with Crohn's disease  
Z. Kiss, N.J. Beres, E. Sziksz, A. Vannay, A. Arato, K.E. Müller, A. Cseh, A.J. Szabo,  
G. Veres (Budapest, HU)
53. One year experience in treating patients with severe ulcerative colitis with biosimilar  
(infliximab) – Remsima®  
A. Koleva, M. Stamboliyska, I.A. Kotzev, A. Angelov (Varna, BG)
54. Our experience with the application of biosimilar infliximab to IBD patients  
M. Konecny (Olomouc, CZ)
55. Significance of serological markers in the disease course of ulcerative colitis  
G. Kovacs, N. Sipeki, K. Palatka, I. Altorjay, K. Fechner, G.L. Norman, Z. Shums,  
G. Veres, P.L. Lakatos, M. Papp (Debrecen, Budapest, HU; Lübeck, DE; San  
Diego, US)
56. Predictive factors for severe Crohn's disease. Results of a Tunisian survey  
M. Labbane, K. Torjmane, S. Zarrouk, Y. Bouteraa, S. Ouerdiane (Bizerta, TN)
57. Natural history of non-severe inflammatory bowel disease at onset  
M. Labbane, S. Zarrouk, K. Torjmane, Y. Bouteraa, S. Ouerdiane (Bizerta, TN)
58. High-resolution anorectal manometry in IBD patients: A pilot study  
A. Ladic, N. Rustemovic, J. Skunca, S. Cukovic-Cavka (Zagreb, HR)
59. Bile acids regulate intestinal epithelial restitution: Implications for pathogenesis  
and therapy of IBD  
N.K. Lajczak, M.S. Mroz, V. Saint-Criq, S.J. Keely (Dublin, IE)
60. Involvement of PARK7 in the pathomechanism of inflammatory bowel disease  
R. Lippai, E. Sziksz, D. Pap, R. Rokonay, A. Veres-Szekely, A. Fekete, A.J. Szabo,  
A. Vannay (Budapest, HU)
61. Ileal inflammation at the resection margin may be predictive for increased risk of  
postoperative Crohn's disease recurrence over a 10 year follow-up  
L. Lynch, I. Hay, E. Saffouri, A. Riley, R. Burgul, D. Watts (Larbert, GB)
62. Early diagnosis of malignancy of colon polyps  
S. Mamatkulov, B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)
63. Determination serum lactoferrin concentration as a way assess treatment of  
ulcerative colitis  
L. Mamedova, G.N. Tarasova, A. Galushkin (Rostov-on-Don, RU)

64. Decreased fibrogenesis in CH25H<sup>-/-</sup> mice in a newly developed mouse model of intestinal fibrosis  
B. Misselwitz, T. Raselli, A. Wyss, C. Mamie, G. Rogler, M. Hausmann (Zurich, CH)
65. Ulcerative colitis patients with complicated interstitial cystitis  
V. Mokricka, P. Zalizko, J. Pokritnieks, K. Snippe, J. Vilmanis, A. Pukitis (Riga, LV)
66. The choice of treatment the patients with ulcerative colitis  
B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)
67. The problem of the treatment of severe ulcerative colitis  
B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)
68. Mucosal healing in ulcerative colitis  
A. Ouakaa-Kchaou, D. Trad, H. Elloumi, M. Sabbah, N. Bibani, D. Gargouri, J. Kharrat (Tunis, TN)
69. New therapeutic approach in ulcerative colitis: Fecal microbiota transplantation  
K. Ozturk, A. Uygun, H. Demirci, C. Oger, I. Avci (Ankara, TR)
70. Factors associated with anxiety and depression in Korean IBD patients  
D. Park (Seoul, KR)
71. Comparing the clinical outcomes between young-onset and adult-onset ulcerative colitis: A multicenter KASID study  
D. Park (Seoul, KR)
72. Early change in faecal calprotectin predicts primary non-response to anti-TNF $\alpha$  therapy in Crohn's disease  
P. Pavlidis, S. Gulati, P. Dubois, G. Chung-Faye, R. Sherwood, I. Bjarnason, B.H. Hayee (London, GB)
73. The efficacy and tolerability of azathioprine therapy in inflammatory bowel disease patients  
K. Pavlovska, M. Slaninka Miceska, I. Kikerkov, E. Atanasovska, V. Avramovski, L. Efremovska (Skopje, MK)
74. Extensive pustular pyoderma gangraenosum: The rare skin extraintestinal manifestation of ulcerative colitis. A case report  
C. Pernat Drobez, G. Vujnovic, P.B. Marko (Maribor, SI)
75. Targeting personalized therapies in IBD: Polymorphisms of IL-4 (C-590T) and GJB2 (35delG) genes associate with pro- and anti-inflammatory cytokines  
O.M. Plehutsa, R.I. Sydorhuk, L.P. Sydorhuk, I.I. Sydorhuk, A.R. Sydorhuk (Chernivtsi, UA)
76. Regulatory role of the transcription factor GATA-3 in ulcerative colitis and blocking of experimental colitis by GATA-3-specific DNAzyme  
V. Popp, K. Gerlach, S. Mott, A. Turowska, H. Garn, R. Atreya, I.C. Ho, H. Renz, M.F. Neurath, B. Weigmann (Erlangen, Marburg, DE; Boston, US)
77. Arterial stiffness as a marker of vascular aging in IBD patients – A pilot study  
R. Prijic, V. Premuzic, M. Jelakovic, A. Kunovic, D. Grgic, M. Brinar, N. Turk, Z. Krznaric, B. Vucelic, S. Cukovic-Cavka (Zagreb, HR)

78. Diagnosis and treatment of Crohn's disease  
S.T. Rakhmanov, B.S. Navruzov (Tashkent, UZ)
79. Can the inflammatory bowel disease biologics registry lead to improved quality of care?  
I. Rikaby, L. Alrubaiy, H.A. Hutchings, J.G. Williams (Cardiff, Swansea, GB)
80. Systematic review of the clinical disease severity indices for inflammatory bowel disease  
I. Rikaby, L. Alrubaiy, M. Sageer, H.A. Hutchings, J.G. Williams (Cardiff, Swansea, GB; Burlington, US)
81. LYC-53976, a ROCK2-selective inhibitor, attenuates the fibrogenic response of intestinal myofibroblasts to TGF-beta and substrate stiffness  
E.S. Rodansky, X. Liu, L.A. Johnson, K. Demrock, A.J. Celeste, L.L. Carter, P.D.R. Higgins (Ann Arbor, US)
82. Factors associated with non-adherence to medication for inflammatory bowel disease: A monocentric Tunisian study  
H. Romdhane, B. Bouchabou, H. Ayadi, R. Ennaifer, M. Cheikh, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)
83. Risk factors for decreased bone mineral density in inflammatory bowel disease in a Tunisian cohort  
H. Romdhane, H. Ayadi, B. Bouchabou, R. Ennaifer, M. Cheikh, H. Ben Nejma, W. Bougassas, N. Belhadj (Tunis, TN)
84. Clinical features of the patients with IBD in Coratia  
B. Rosic Despalatovic, A. Bratanic, M. Simunic, A. Tonkic (Split, HR)
85. Incidence and severity of pre-pouch ileitis: A distinct disease entity or a manifestation of refractory pouchitis? A retrospective cohort study of patients from Amsterdam, Leuven and London  
M.A. Samaan, D. de Jong, S. Sahami, S. Morgan, K. Fragkos, S. Subramaniam, K. Kok, J. Makanyanga, I. Barnova, H. Saravanapavan, I. Parisi, S. Di Caro, R. Vega, F. Rahman, S. McCartney, S.L. Bloom, G.R. van den Brink, M. Löwenberg, C.Y. Ponsioen, C.J. Buskens, P.J. Tanis, A. de Buck van Overstraeten, A. D'Hoore, W. A. Bemelman, G. D'Haens (London, GB; Amsterdam, NL; Leuven, BE)
86. IL-36R signalling in intestinal epithelial cells and fibroblasts promotes mucosal healing in vivo  
K. Scheibe, M.F. Neurath, C. Neufert (Erlangen, DE)
87. 5-HT7 receptor mechanism for stress-induced analgesia: A new therapeutic target for inflammatory pain  
M. Seyrek, Y.S. Sakin, O. Yesilyurt, M. Leopoldo, A. Dogrul (Ankara, TR; Bari, IT)
88. Extraintestinal manifestations in inflammatory bowel disease (IBD) among Egyptian patients: A tertiary center experience  
M. Sharaf-Eldin, M. Enaba, S. Abousaif (Tanta, EG)
89. Thalidomide therapy for vascular malformations of the gastrointestinal tract  
S. Surgenor, J. Snook (Poole Dorset, GB)



90. Approaching personalized therapy for IBD: ACE gene's polymorphisms participate in IBD pathogenesis through changes of colonic microbiota and mesenteric vascularization  
A.R. Sydorchuk, T.M. Boychuk, L.P. Sydorchuk, R.I. Sydorchuk, O.M. Plehutsa, I.I. Sydorchuk (Chernivtsi, Kiev, UA)
91. Targeting colonic microbiota in IBD: Oral probiotic therapy  
L.P. Sydorchuk, T.M. Boychuk, R.I. Sydorchuk, I.I. Sydorchuk, O.M. Plehutsa, A.R. Sydorchuk (Chernivtsi, UA)
92. Mesalazine vs. probiotic use in maintaining remission in IBD  
R.I. Sydorchuk, T.M. Boychuk, L.P. Sydorchuk, I.I. Sydorchuk, O.M. Plehutsa, A.R. Sydorchuk (Chernivtsi, UA)
93. Is it Crohn's disease (CD) or intestinal TB (iTb), dilemma that can lead to a catastrophe: Case report  
Y. Taher, M. Sharaf-Eldin (Tanta, EG)
94. Correlation of MR enterography parameters with clinical and endoscopic disease activity indices  
O. Tayfur Yurekli, A. Demirezer Bolat, N.S. Büyükasik, O. Algin, H. Koseoglu, M. Tahtaci, O. Ersoy (Ankara, TR)
95. The influence of the modified symbiotic bacteria metabolites on immune cells  
G. Tereshchuk, D. Vatlitsov (Kiev, UA)
96. 7-alpha-cholestenone and faecal calprotectin in patients with collagenous colitis  
R.C. Trimble, D.E. Yung, A. Koulaouzidis (Edinburgh, GB)
97. Hyperbaric oxygen therapy in ulcerative colitis treatment  
A. Uzunova-Genova (Sofia, BG)
98. The metabolic deregulation as response on different kind of stress load  
D. Vatlitsov, N. Rusetskaya (Kiev, UA)
99. Acute hepatitis in a patient receiving multiple therapies for Crohn's disease: A case report  
I.K. Williams, S. Surgenor (Poole Dorset, GB)
100. Adding stewed apricot juice to senna improves the right-side and overall colon cleansing quality for colonoscopy preparation  
B. Yasar, E. Abut, H. Kayadibi, F. Akdogan, C. Gonen (Istanbul, Adana, TR)
101. Patients with Crohn's disease: The hydrogen breath test  
E.V. Zygalo, L. Demeshkina, O.V. Sorochnan, V. Kudryavtseva (Dnipropetrovsk, UA)

# List of Speakers, Moderators and Scientific Organizers

## **Dr. Martin Bortlik**

Clinical and Research  
Center for IBD  
Iscare I.V.F. a.s., Lighthouse  
Jankovcova 1569/2c  
170 04 Prague  
Czech Republic  
mbortlik@hotmail.com

## **Prof. Dr. Jacques Cosnes**

Service de Gastroentérologie  
and Nutrition  
Hôpital Saint Antoine  
184, Rue du Faubourg St.-Antoine  
75012 Paris  
France  
jacques.cosnes@aphp.fr

## **Dr. Mircea Diculescu**

Department of Gastroenterology  
Fundeni Clinical Hospital  
and Hepatology  
Sos. Fundeni 258  
022328 Bucharest  
Romania  
mmdiculescu@yahoo.com

## **Prof. Dr. Axel Dignass**

Medizinische Klinik I  
AGAPLESION  
Markus Krankenhaus  
Wilhelm-Epstein-Str. 4  
60431 Frankfurt  
Germany  
axel.dignass@fdk.info

## **Prof. Dr. Andrey E. Dorofeyev**

National Medical University  
n.a. A.A.Bogomoletz  
Chair of Internal Diseases#1  
Shevchenko bul.17  
01030 Kiev  
Ukraine  
dorofeyev@med.finfort.com

## **Dr. Pavel Drastich**

Assoc. Prof. of Internal Medicine  
Department of Hepatogastroenterology  
Institute for Clinical and  
Experimental Medicine  
14021 Prague  
Czech Republic  
drastich@hotmail.com

## **Dr. Dana Duricova**

Clinical and Research  
Center for IBD  
Iscare I.V.F. a.s., Lighthouse  
Jankovcova 1569/2c  
170 04 Prague  
Czech Republic  
dana.duricova@seznam.cz

## **Prof. Dr. Marc Ferrante**

Department of Gastroenterology  
University Hospitals Leuven  
KU Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
marc.ferrante@uz.kuleuven.ac.be

## **Prof. Dr. Geoffrey M. Forbes**

Department of Gastroenterology  
and Hepatology  
Royal Perth Hospital  
Box X2213 GPO  
Perth, WA 6847  
Australia  
geoff.forbes@health.wa.gov.au

## **Dr. Marc Martí Gallostra**

Consultant Colorectal Unit  
Digestive and General Surgery  
Hospital Universitari Vall D'Hebron  
Barcelona  
Spain  
marcmartig@gmail.com

**Prof. Dr. Ann Gils**

Therapeutic and  
Diagnostic Antibodies O&N II  
Herestraat 49 - box 820  
3000 Leuven  
Belgium  
ann.gils@pharm.kuleuven.be

**Prof. Dr. Chris J. Hawkey**

Professor of Gastroenterology  
Nottingham Digestive Disease Centre  
University Hospital  
Nottingham NG7 2UH  
Great Britain  
cj.hawkey@nottingham.ac.uk

**Peter D. R. Higgins, M.D.**

Associate Professor of Medicine  
Department of Gastroenterology  
University of Michigan  
Medical Science Res. Bldg. I  
1150 W Medical Ctr Dr.  
Ann Arbor, MI 48109-0682  
USA  
phiggins@med.umich.edu

**Prof. Dr. Tibor Hlavaty**

Dept. of Internal Medicine  
Sub-dept. of Gastroenterology  
and Hepatology  
University Hospital Bratislava  
Ruzinovska 6  
82606 Bratislava  
Slovakia  
tibor.hlavaty2@gmail.com

**Dr. Jorgen Jahnsen**

Akerhus Regional Hospital  
Postboks 75 Akershus  
1474 Nordbyhagen  
Norway  
jorgen.jahnsen@medisin.uio.no

**Prof. Dr. Wolfgang Kruis**

Innere Medizin  
Evang. Krankenhaus Kalk  
Buchforststr. 2  
51103 Köln  
Germany  
kruis@evkk.de

**Prof. Dr. Peter L. Lakatos**

Semmelweis University  
Medical School  
I Department of Medicine  
Koranyi u. 2/a  
1083 Budapest  
Hungary  
lakatos.peter\_laszlo@  
med.semmelweis-univ.hu

**Prof. Dr. Milan Lukas**

Clinical and Research  
Center for IBD  
Iscare I.V.F. a.s., Lighthouse  
Jankovcova 1569/2c  
170 04 Prague  
Czech Republic  
milan.lukas@email.cz

**Dr. Tamás Molnár**

First Department of Medicine  
University of Szeged  
Korányi fasor 8-10  
6720 Szeged  
Hungary  
molnar.tamas@med.u-szeged.hu

**Prof. Dr. Bjorn Moum**

Department of Gastroenterology  
Clinics of Medicine  
Oslo University Hospital Ullevaal  
& University Oslo  
Kirkeveien 166  
0424 Oslo  
Norway  
bjorn.moum@medisin.uio.no

**Prof. Dr. Gottfried Novacek**

Medizinische Universität Wien  
Gastroenterologie/Hepatoogie  
Währinger Gürtel 18-20  
1090 Wien  
Austria  
gottfried.novacek@meduniwien.ac.at

**Dr. Julius Orhalmi**

Department of Surgery  
Charles University Hospital  
Hradec Kralove  
Czech Republic  
orhalmi@volny.cz

**Prof. Dr. Yves Panis**

Service de Chirurgie Colorectale  
Pôle des Maladies de l'Appareil Digestif  
(PMAD)  
Hôpital Beaujon  
100 bd du Gal Leclerc  
92118 Clichy Cedex  
France  
yves.panis@bjn.aphp.fr

**Dr. Marijana Protic**

Assoc. Professor  
Department of Gastroenterology  
and Hepatology  
University Hospital Zvezdara  
Dimitrija Tucovica 161  
Belgrade  
Serbia  
marijana.n.protic@gmail.com

**Prof. Dr. Walter Reinisch**

Department of Medicine  
Health Sciences Centre  
McMaster University  
1280 Main Street West  
Hamilton, ON L8S 4K1  
Canada  
reinisw@mcmaster.ca

**Florian Rieder, M.D.**

Department of Gastroenterology  
and Hepatology  
Lerner Research Institute  
Cleveland Clinic Foundation  
Cleveland, OH 44195  
USA  
riederf@ccf.org

**Prof. Dr. Dr. Gerhard Rogler**

Universitätsspital Zürich  
Klinik für Gastroenterologie  
und Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
gerhard.rogler@usz.ch

**Bruce E. Sands, M.D.**

Professor of Medicine  
Department of Gastroenterology  
Mount Sinai School of Medicine  
One Gustave L. Levy Place  
New York NY 10029  
USA  
bruce.sands@mssm.edu

**Prof. Dr. Jürgen Schölmerich**

Klinikum der Johann Wolfgang  
Goethe-Universität Frankfurt  
Theodor-Stern-Kai 7  
60596 Frankfurt  
Germany  
aed@kgu.de

**Dr. Zuzana Serclova**

Surgical Department  
University Hospital Bulovka  
Prague  
Czech Republic  
sercl@seznam.cz

**Prof. Dr. Eduard F. Stange**

Gastroenterologie / Hepatologie  
Robert-Bosch-Krankenhaus  
Auerbachstr. 110  
70376 Stuttgart  
Germany  
eduard.stange@rbk.de

**Prof. Dr. Helena Tlaskalová-Hogenová**

Department of Immunology  
and Gnotobiology  
Institute of Microbiology  
Academy of Sciences of the Czech Republic  
Prague  
Czech Republic  
tlaskalo@biomed.cas.cz

**Dr. Zuzana Zelinkova**

IBD Centrum  
5th Dept. of Internal Medicine  
Tomasikova 50/C  
831 04 Bratislava  
Slowakei  
zelinkova@assiduo.sk

## Congress Office

**During** the Symposium 202

Hilton Prague  
Pobrezni 1  
18600 Prague 8  
Czech Republic

Telephone: +49 (0)175/7795327

### **Opening Hours:**

Thursday, April 28, 2016	16.00 – 21.00 h
Friday, April 29, 2016	7.00 – 17.30 h
Saturday, April 30, 2016	8.30 – 16.45 h

## Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

## Congress Report


The official congress report of the Symposium 202 “Evolving Therapies in Clinical Practice in IBD” will be published in English in the second half of 2016 by Karger, Switzerland. Orders for this book at a reduced subscription price of EUR 35,- can be placed at the Congress Office during the congress in Prague.

## Congress Short Report

The congress short report of the Falk Symposium 202 “Evolving Therapies in Clinical Practice in IBD” will be published by the Falk Foundation e.V. with number FSR 202 in the second half of 2016.

## Directions





## General Information:

FALK FOUNDATION e.V.



Leinenweberstr. 5  
79108 Freiburg  
Germany

Congress Department

Telephone: +49 (0) 761/15 14-125

Telefax: +49 (0) 761/15 14-359

E-Mail: [symposia@falk-foundation-symposia.org](mailto:symposia@falk-foundation-symposia.org)

[www.falk-foundation-symposia.org](http://www.falk-foundation-symposia.org)